60 Degrees Pharmaceuticals Signs Exclusive Patent License Agreement with Florida State University for Non-Prescription Use of Australian Chestnut Extract as a Botanical Supplement
60 Degrees Pharmaceuticals Announces Early Enrollment of First Seasonal Patient in Clinical Trial of Tafenoquine for Patients Hospitalized with Babesiosis
60 Degrees Pharmaceuticals Announces Early Enrollment of First Seasonal Patient in Clinical Trial of Tafenoquine for Patients Hospitalized with Babesiosis
60 Degrees Pharmaceuticals Announces First Quarter 2026 Results
60 Degrees Pharmaceuticals Inc. (NASDAQ:SXTP) Sees Significant Decline in Short Interest
60 Degrees Pharmaceuticals Inc. (SXTP) Upgraded to Buy: Here's What You Should Know
60 Degrees Pharmaceuticals Announces 2025 Annual Results
60 Degrees Pharmaceuticals Files New Dietary Ingredient Notification (NDIN) with FDA for Australian Chestnut Extract
What's Going On With 60 Degrees Pharmaceuticals On Friday?
60 Degrees Pharmaceuticals Announces All Patients Cured of Babesiosis After Tafenoquine Treatment in Expanded Use Clinical Trial
Analyzing Rafael (NYSE:RFL) & 60 Degrees Pharmaceuticals (NASDAQ:SXTP)
60 Degrees Pharmaceuticals Expands Access to ARAKODA® with GoodRx Partnership
60 Degrees Pharmaceuticals (NASDAQ:SXTP) Shares to Reverse Split on Tuesday, January 20th
60 Degrees Pharmaceuticals, Inc. Announces Approval of Reverse Stock Split Ratio
60 Degrees Pharmaceuticals Announces Detection of Babesia Infection in 24 Percent of Patients Presenting with Chronic Fatigue in Peer-Reviewed, Sponsored Study at NC State
Here's Why 60 Degrees Pharmaceuticals Inc. (SXTP) Looks Ripe for Bottom Fishing
60 Degrees Pharmaceuticals Announces Expansion of ARAKODA® Sales and Marketing in 2026
60 Degrees Pharmaceuticals Announces Clinical Site Now Open for Patient Enrollment for the B-FREE Chronic Babesiosis Study at Mount Sinai Icahn School of Medicine
60 Degrees Pharmaceuticals Announces Third Quarter 2025 Results
60 Degrees Pharmaceuticals Announces No Detection of Babesia Infection in First Patient Following Treatment with Tafenoquine in Relapsing Babesiosis Study
60 Degrees Pharmaceuticals Unveils Name of Chronic Babesiosis Clinical Trial: B-FREE Chronic Babesiosis Study
60 Degrees Pharmaceuticals Live Webcast Link and New Date for Presentation at H.C. Wainwright 27th Annual Global Investment Conference
60 Degrees Pharmaceuticals to Present at H.C. Wainwright 27th Annual Global Investment Conference
60 Degrees Pharmaceuticals Selects Icahn School of Medicine at Mount Sinai as Central Clinical Trial Site for Phase II Study to Evaluate Tafenoquine for Chronic Babesiosis
60 Degrees Pharmaceuticals Announces Second Quarter 2025 Results
60 Degrees Pharmaceuticals Announces Closing of up to $10 Million Public Offering
60 Degrees Pharmaceuticals Announces Pricing of Up to $10 Million Public Offering
60 Degrees Pharmaceuticals Defines Potential Human Babesiosis Market Size for ARAKODA® (tafenoquine): Annual Max TAM, Sales of $245 Million; Cumulative through Patent Expiration, $1.1 Billion
60 Degrees Pharmaceuticals Expands Options for Malaria Prevention with Introduction of ARAKODA® (tafenoquine) 8-Count Bottle Format
Babesiosis Incidence in U.S. 10x Higher Than CDC Estimates, According to Insurance Claims Study Commissioned by 60 Degrees Pharmaceuticals
60 Degrees Pharmaceuticals Announces First Quarter 2025 Results
Babesiosis Disease Burden in United States is Substantially Higher Than Official Estimates, According to Preliminary Results of 60 Degrees Pharma Survey
Geoff Dow, PhD, Infectious Disease Product Development Expert, to Discuss Babesiosis at Healing Lyme Summit, April 15-21
Sixty Degrees Pharmaceuticals Announces Patent License Agreement to Advance Development of Tafenoquine for Babesiosis Treatment and Prevention with Yale School of Medicine and Yale School of Public Health
60 Degrees Pharmaceuticals and Fathom Holdings Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
60 Degrees Pharmaceuticals, Inc. Announces 1:5 Reverse Stock Split
Sixty Degrees Pharmaceuticals to Ensure Continuity of Tafenoquine Supply in U.S. by Importing Limited Quantity of KODATEF®
60 Degrees Pharma Announces Closing of $1.075 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
60 Degrees Pharma Announces $1.075 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
60 Degrees Pharma Announces Closing of $1.043 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
60 Degrees Pharma Announces IRB Approval of Phase II Study to Evaluate Tafenoquine for Chronic Babesiosis
60 Degrees Pharmaceuticals Enrolls First Patient in Tafenoquine Expanded Access Clinical Study for Persistent (B. microti) Babesiosis
Sixty Degrees Pharmaceuticals and Tufts Medical Center Announce Patent License Agreement to Advance Development of Tafenoquine for Babesiosis Treatment and Prevention
60 Degrees Pharmaceuticals Expands Tafenoquine Clinical Trial for Babesiosis to Brigham and Women's Hospital
60 Degrees Pharmaceuticals and Can-Fite BioPharma Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
60 Degrees Pharmaceuticals Inc. (SXTP) Reports Q3 Loss, Misses Revenue Estimates
60 Degrees Pharmaceuticals Announces Third Quarter 2024 Results
60 Degrees Pharmaceuticals Inc. Announces ARAKODA® Promotional Pilot in Advance of Expanded U.S. Launch
60 Degrees Pharmaceuticals, Inc. Announces $4 Million Private Placement Priced At-the-Market Under Nasdaq Rules
60 Degrees Pharmaceuticals, Inc. Regains Compliance with Nasdaq Listing Requirements